Executive Summary
Medical technology is one of the slowest sectors to adopt AI — lagging finance, retail, and other high-tech industries by an estimated 50%. The cause is structural, not technological.
Three barriers compound to create the lag. First, the predicate problem: the substantial-equivalence framework that governs the 82% of medical devices cleared via 510(k) is poorly suited to AI/ML devices that update post-clearance. Second, the validated-state paradox: AI systems improve through continuous learning, but the regulatory regime requires devices to remain in a validated state. Third, the clinical evidence gap: 25% of recent AI/ML device submissions included no clinical study at all, raising reviewer concerns and feeding the cycle of caution.
This paper analyzes the structural barriers to AI adoption in medical technology — and the regulatory infrastructure that could resolve them.
Key Findings
- Only 24% of medical technology companies use AI in any meaningful capacity — a 50% adoption lag versus other high-tech sectors.
- 82% of medical devices are cleared via the 510(k) substantial-equivalence pathway, which was not designed for AI/ML.
- 25% of recent AI/ML medical-device submissions included no clinical study.
- The 'validated state' requirement creates a paradox for AI systems designed to improve through continuous learning.
- The FDA's Predetermined Change Control Plan (PCCP) framework is a partial answer, but adoption is uneven across sponsors.
Read the full analysis
The full white paper — including methodology, source citations, and detailed analysis of each finding — is available as a downloadable PDF.